<DOC>
	<DOCNO>NCT01933945</DOCNO>
	<brief_summary>This study collect data patient treat TACE follow sorafenib hepatocellular carcinoma ( HCC ) patient without Sorafenib TACE . In contrast prior observational study sorafenib ( GIDEON study ) , pre-treatment TACE document retrospectively , study collect detail information TACE treatment status patient treatment sorafenib start .</brief_summary>
	<brief_title>Outcomes HCC ( Hepatocellular Carcinoma ) Patients Treated With TACE ( Transarterial Chemoembolization ) Early , Not Early Not All Followed Sorafenib</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients histologically/cytologically document radiographically diagnose HCC . Radiographic diagnosis need typical finding HCC radiographic method i.e . multidimensional dynamic CT , CT hepatic arteriography ( CTHA ) /CT arterial portography ( CTAP ) MRI . Patients BCLC ( Barcelona clinic liver cancer stag ) stage B high . Patients decision treat TACE make time study enrollment . Patients receive one TACE past also enrol , TACE do site require data previous TACEs available . TACE include conventional TACE lipidiol ( similar agent ) chemotherapeutic agent ( ) TACE DC Beads exclude TAE without chemotherapeutic agent . Patients unresectable HCC ( incurable curative treatment include resection ablation eligible resection local ablation ) Patients must sign informed consent form Patients must life expectancy least 8 week Patients receive TACE past data TACE require protocol available Patients receive systemic anticancer therapy prior first TACE Patients treat accord trial protocol intervention include locoregional therapy systemic therapy Hospice patient All contraindication accord local marketing authorization consider .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>